Edgewise Therapeutics (EWTX) Total Current Liabilities (2020 - 2026)

Edgewise Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $22.5 million in Q1 2026.

• Quarterly Total Current Liabilities rose 6.76% year-over-year to $22.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.5 million (up 6.76% YoY) and the FY2025 annual result came in at $27.4 million, up 14.71% from the prior year.
• Total Current Liabilities fell to $22.5 million in Q1 2026 per EWTX's latest filing, from $27.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $27.4 million in Q4 2025 and troughed at $9.2 million in Q2 2022.
• A 5-year average of $17.5 million and a median of $16.8 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 106.23% in 2022, then increased 1.12% in 2023.
• Over 5 years, Total Current Liabilities stood at $16.6 million in 2022, then rose by 1.12% to $16.8 million in 2023, then surged by 42.27% to $23.9 million in 2024, then advanced by 14.71% to $27.4 million in 2025, then slipped by 17.64% to $22.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $22.5 million, $27.4 million, and $21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.